Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Meeting Planned To Discuss Drug-Eluting Device Death Risk

Executive Summary

Two trials of paclitaxel-coated devices to treat peripheral arterial disease have been halted in recent weeks due to reports the devices were tied to a higher mortality risk. Endovascular physician group VIVA is organizing a February meeting to discuss the issue. Two trials of paclitaxel-coated devices to treat peripheral arterial disease have been halted in recent weeks due to reports the devices were tied to a higher mortality risk. Endovascular physician group VIVA is organizing a February meeting to discuss the issue.

Advertisement

Related Content

Paclitaxel-Coated PAD Devices Under US FDA Scrutiny

Topics

Advertisement
UsernamePublicRestriction

Register

MT124409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel